Jake Bauer - 01 May 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: Director
Issuer ticker: IMVT
Reported as of: 01 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 May 2025, 19:30:07 UTC
Prior SEC filing: 28 Apr 2025
Next SEC filing: 18 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Christopher Van Tuyl, Attorney-in-Fact for Jacob Bauer

Key filing fact

Jake Bauer filed Form 4 for Immunovant, Inc. (IMVT) on 05 May 2025.

Key facts

This page summarizes Jake Bauer's Form 4 filing for Immunovant, Inc. (IMVT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 May 2025, 19:30.

Change

Previous filing in this sequence was filed on 28 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001654909 Primary reporting owner

Bauer Jake

Relationship: Director
Address: C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK
Signature: /s/ Christopher Van Tuyl, Attorney-in-Fact for Jacob Bauer
Signature date: 05 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock

Award

Transaction value: $0
Shares: +25,016
Change %
Price: $0.000000
Shares after: 25,016
Date: 01 May 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMVT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +35,234
Change %
Price: $0.000000
Shares after: 35,234
Date: 01 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,234
Exercise price: $15.90
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in three equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date.

Footnote F2

These options were granted pursuant to the Plan. The shares underlying the options will vest in three equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date.